Price
$8.76
Decreased by -5.09%
Dollar Volume
4.58 M
ADR%
6.87
Earnings Report Date (estimate)
Mar 13, 23 (-0.57)
Market Cap.
375.38 M
Shares Float
24.15 M
Shares Outstanding
42.85 M
Beta
2.06
Price / Earnings
-8.35
BPR
4.82
20D Range
7.42 9.52
50D Range
7.42 20.88
200D Range
7.42 21.87
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.53
Decreased by -20.45%
-0.53
Aug 10, 22 -0.56
Decreased by -64.71%
-0.45
Decreased by -24.44%
May 12, 22 0.10
Increased by +112.20%
-0.18
Increased by +155.56%
Mar 15, 22 -0.47
Decreased by -2.17%
-0.42
Decreased by -11.90%
Nov 10, 21 -0.44
Increased by +84.51%
-0.44
Aug 12, 21 -0.34
Increased by +67.62%
-0.53
Increased by +35.85%
May 17, 21 -0.82
Increased by +38.35%
-0.49
Decreased by -67.35%
Mar 11, 21 -0.46
Increased by +91.68%
-0.88
Increased by +47.73%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by -100.00%
-22.00 M
Decreased by -56.97%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-22.54 M
Decreased by -107.65%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 24.99 M
Increased by +727.73%
4.62 M
Increased by +121.66%
Increased by +18.48%
Decreased by -96.55%
Dec 31, 21 6.02 M
Increased by +11.28%
-15.81 M
Decreased by -76.52%
Decreased by -262.67%
Decreased by -58.64%
Sep 30, 21 3.43 M
Increased by +13.24%
-14.01 M
Increased by +5.18%
Decreased by -408.66%
Increased by +16.27%
Jun 30, 21 4.81 M
Decreased by -35.51%
-10.85 M
Decreased by -28.37%
Decreased by -225.47%
Decreased by -99.07%
Mar 31, 21 -3.98 M
Decreased by -299.05%
-21.32 M
Decreased by -375.23%
Increased by +535.52%
Increased by +338.75%
Dec 31, 20 5.41 M
Increased by +174.76%
-8.96 M
Decreased by -36.18%
Decreased by -165.58%
Increased by +50.44%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.